Bladder Cancer
Summary
The bladder cancer market in the seven major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, and Japan) has remained largely unchanged in the past 10-20 years. However, significant expansion is expected starting in 2016, with the introduction of several new therapies that are projected to fuel market growth. In addition, bladder cancer has a robust early-stage pipeline that will contribute to market growth during the forecast period. Currently, the bladder cancer market is dominated by generic chemotherapy and immunotherapy. Though initially effective, toxicity and lack of clinical efficacy in improving overall survival have left the door open for more tolerable and effective drugs to be developed. In the past, bladder cancer has not been an area of focus for pharmaceutical companies, but that is rapidly changing as more companies focus on the bladder cancer market, recognizing the high level of unmet need and relatively clear regulatory path. During the forecast period, the market landscape will begin to change dramatically with the introduction of newer immunotherapies, specifically, PD-1 checkpoint modulators, of which five are expected to launch by 2025. These drugs will provide much-needed alternatives to bladder cancer patients who have not benefitted from traditional treatments.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1579667-opportunityanalyzer-bladder-cancer-opportunity-analysis-and-forecasts-to-2025
Scope of The Report
- Overview of bladder cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline Bladder cancer market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting bladder cancer therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global bladder cancer therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the bladder cancer therapeutics market in the future.
Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 8
2 Bladder Cancer: Executive Summary 10
2.1 Bladder Cancer Market in the 7MM Expected To Triple in Size From 2015 to 2025 11
2.2 Big Pharma Focuses on Label Expansion, While Smaller Companies Focus on Developing Drugs with Novel Mechanisms of Action 12
2.3 The Levels of Unmet Need Remain High Across Bladder Cancer Settings 13
2.4 Pipeline Agents Will Reduce Unmet Need, but Opportunities Remain 13
2.5 NMIBC Settings Are Not Expected to Change Significantly, While PD-1 Checkpoint Inhibitors Are Expected to Gain Stronghold in Advanced Disease Settings 14
2.6 What Do Physicians Think? 17
3 Disease Overview 19
3.1 Etiology and Pathophysiology 19
3.1.1 Etiology 19
3.1.2 Pathophysiology 20
3.2 Classification or Staging Systems 21
3.3 Symptoms 24
3.4 Prognosis 25
3.5 Quality of Life 25
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1579667-opportunityanalyzer-bladder-cancer-opportunity-analysis-and-forecasts-to-2025
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Summary
The bladder cancer market in the seven major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, and Japan) has remained largely unchanged in the past 10-20 years. However, significant expansion is expected starting in 2016, with the introduction of several new therapies that are projected to fuel market growth. In addition, bladder cancer has a robust early-stage pipeline that will contribute to market growth during the forecast period. Currently, the bladder cancer market is dominated by generic chemotherapy and immunotherapy. Though initially effective, toxicity and lack of clinical efficacy in improving overall survival have left the door open for more tolerable and effective drugs to be developed. In the past, bladder cancer has not been an area of focus for pharmaceutical companies, but that is rapidly changing as more companies focus on the bladder cancer market, recognizing the high level of unmet need and relatively clear regulatory path. During the forecast period, the market landscape will begin to change dramatically with the introduction of newer immunotherapies, specifically, PD-1 checkpoint modulators, of which five are expected to launch by 2025. These drugs will provide much-needed alternatives to bladder cancer patients who have not benefitted from traditional treatments.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1579667-opportunityanalyzer-bladder-cancer-opportunity-analysis-and-forecasts-to-2025
Scope of The Report
- Overview of bladder cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline Bladder cancer market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting bladder cancer therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global bladder cancer therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the bladder cancer therapeutics market in the future.
Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 8
2 Bladder Cancer: Executive Summary 10
2.1 Bladder Cancer Market in the 7MM Expected To Triple in Size From 2015 to 2025 11
2.2 Big Pharma Focuses on Label Expansion, While Smaller Companies Focus on Developing Drugs with Novel Mechanisms of Action 12
2.3 The Levels of Unmet Need Remain High Across Bladder Cancer Settings 13
2.4 Pipeline Agents Will Reduce Unmet Need, but Opportunities Remain 13
2.5 NMIBC Settings Are Not Expected to Change Significantly, While PD-1 Checkpoint Inhibitors Are Expected to Gain Stronghold in Advanced Disease Settings 14
2.6 What Do Physicians Think? 17
3 Disease Overview 19
3.1 Etiology and Pathophysiology 19
3.1.1 Etiology 19
3.1.2 Pathophysiology 20
3.2 Classification or Staging Systems 21
3.3 Symptoms 24
3.4 Prognosis 25
3.5 Quality of Life 25
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1579667-opportunityanalyzer-bladder-cancer-opportunity-analysis-and-forecasts-to-2025
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
